Vion Pharmaceuticals has received a green light from the FDA to resume studying the cancer drug Cloretazine as regulators removed a clinical hold on a Phase III trial of the therapy. The late stage study of Cloretazine in combination with cytarabine for acute relapsed myeloid leukemia was put on hold after researchers raised concerns over an increase of death relative to the control arm of the trial matching cytarabine and a placebo. But a review found no reason to believe there was any unexpected toxicity playing a role in the deaths.
- read this release for more
- here's the report from Thomson Financial